References
- Magrath I T, Janus C, Edwards B K, Spiegel R, Jaffe E S, Berard C W, et al. An effective therapy for both undifferentiated (including Burkitt's) lymphomas and lymphoblastic lymphomas in children and young adults. Blood 1984; 63: 1102–1111
- Tu P H, Giannni C, Judkins A R, Schwalb J M, Burack R, O'Neill B P, et al. Clinicopathologic and genetic profile of intracranial marginal zone lymphoma: a primary low-grade CNS lymphoma that mimics meningioma. J Clin Oncol 2005; 23: 5718–5727
- van Besien K, Ha C S, Murphy S, McLaughlin P, Rodriguez A, Amin K, et al. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood 1998; 91: 1178–1184
- Zucca E, Conconi A, Mughal T I, Sarris A H, Seymour J F, Vitolo U, et al. Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol 2003; 21: 20–27
- Boehme V, Zeynalova S, Kloess M, Loeffler M, Kaiser U, Pfreundschuh M, et al. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma – a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol 2007; 18: 149–157
- The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's Lymphoma. Blood 1997; 89: 3909–3918
- Jaffe E S, Harris N L, Stein H, Vardiman J W. World Health Organisation Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, IARC Press 2001
- Oinonen B, Franssila K, Elonen E. Central nervous system involvement in patients with mantle cell lymphoma. Ann Hematol 1999; 78: 145–149
- Valdez R, Kroft S H, Ross C W, Schnitzer B, Singleton T, Peterson L C, Finn W G. Cerebrospinal fluid involvement in mantle cell lymphoma. Mod Pathol 2002; 15: 1073–1079
- Ferrer A, Bosch F, Villamor N, Rozman M, Graus F, Guttierrez G, et al. Central nervous system involvement in mantle cell lymphoma. Ann Oncol 2008; 19: 135–141
- Gill S, Prince H M, Wolf M M, Wirth A, Ryan G, Carney D, et al. Mantle cell lymphoma with central nervous involvement: frequency and clinical features. Ann Oncol 2008; 19(Suppl. 4)iv83, (Abstr. 438)
- Dierickx D, Wlodarska I, Vanhentenrijk V, De Wolf-Peeters C, Devos T, Delforge M, et al. Secondary central nervous system involvement in cyclin D1-negative mantle cell lymphoma. Leuk Lymphoma 2008; 49: 2365–2366
- Fu K, Weisenburger D D, Greiner T C, Dave S, Wright G, Rosenwald A, et al. Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood 2005; 106: 4315–4321
- Wlodarska I, Dierickx D, Vanhentenrijk V, Van Roosbroeck K, Pospisilova H, Minnei F, et al. Translocations targeting CCND2, CCND3 and MYCN do occur in t(11;14)-negative mantle cell lymphoma. Blood 2008; 111: 5683–5690
- Gill S and Ritchie D. Therapeutic options in mantle cell lymphoma. Leuk Lymphoma 2008; 49: 398–409
- Ritchie D S, Seymour J F, Grigg A P, Roberts A W, Hoyt R, Thompson S, et al. The Hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem-cell transplantation produces excellent event-free survival in patients with previously untreated mantle-cell lymphoma. Ann Haematol 2007; 86: 101–105